2 minute read
HowMuchWeKnowTheSideEffectsOfSunitinibMalate?
www.aasraw.com drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach.
Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA’s Safe Disposal of Medicines website for more information if you do not have access to a take-back program.
Advertisement
How Much We Know The Side Effects Of Sunitinib Malate?
Sunitinib Malate adverse events are considered somewhat manageable and the incidence of serious adverse events low.
The most common adverse events associated with Sunitinib Malate therapy are fatigue, diarrhea, nausea, anorexia, hypertension, a yellow skin discoloration, hand-foot skin reaction, and stomatitis.In the placebo-controlled Phase III GIST study, adverse events which occurred more often with Sunitinib Malate than placebo included diarrhea, anorexia, skin discoloration, mucositis/stomatitis, asthenia, altered taste, and constipation. Dose reductions were required in 50% of the patients studied in RCC in order to manage the significant toxicities of this agent.
Serious (grade 3 or 4) adverse events occur in ≤10% of patients and include hypertension, fatigue, asthenia, diarrhea, and
7
AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com
www.aasraw.com chemotherapy-induced acral erythema. Lab abnormalities associated with Sunitinib Malate therapy include lipase, amylase, neutrophils, lymphocytes, and platelets. Hypothyroidism and reversible erythrocytosis have also been associated with Sunitinib Malate. Most adverse events can be managed through supportive care, dose interruption, or dose reduction.
A recent study done at MD Anderson Cancer Center compared the outcomes of metastatic renal cell cancer patients who received Sunitinib Malate on the standard schedule (50 mg/4 weeks on 2 weeks off) with those who received Sunitinib Malate with more frequent and short drug holidays (alternative schedule). It was seen that the overall survival, progression free survival and drug adherence were significantly higher in the patients who received Sunitinib Malate on the alternative schedule. Patients also had a better tolerance and lower severity of adverse events which frequently lead to discontinuation of treatment of metastatic renal cell cancer patients.
8
